Oxis International's Innovative Cancer Therapies Will Be Profiled on Fox Business Network
LOS ANGELES, CA / ACCESSWIRE / July 19, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that the company's innovative cancer therapies will be profiled on Fox Business Network on Sunday, July 24, at 12:30 p.m. Eastern time.
Anthony J. Cataldo, chief executive of Oxis, discussed the company's drugs for the treatment of cancer and other unmet medical needs on the program Worldwide Business with Kathy Ireland.
Mr. Cataldo discussed the company's promising drug, OXS-1550, which is currently part of an FDA Phase 1/Phase 2 clinical trial at the University of Minnesota's cancer center.
OXS-1550 has shown promise in the treatment of Non-Hodgkin's Lymphoma, one of the deadliest types of cancer. The drug targets and destroys cancer cells, while leaving healthy cells alone and creating far fewer side effects than chemotherapy and other cancer treatments.
"The ability to deliver targeted immunotherapy to a patient could eliminate the use of chemotherapy," Mr. Cataldo said.
Mr. Cataldo said that the coverage by Worldwide Business with Kathy Ireland is important for the company.
"Oxis is presently little known to the publicly traded markets," he said. "Being featured on Worldwide Business with Kathy Ireland allows Oxis to be introduced to a wide market helping to put the achievements of Oxis front and center."
Oxis, through its subsidiary, Oxis Biotech, is working on a broad range of drugs that target cancer, including triple negative breast cancer, multiple myeloma and lymphoma.
To learn more about the company, watch the Kathy Ireland show Sunday, July 24, at 12:30 Eastern time on Fox Business Network.
ABOUT OXIS INTERNATIONAL, INC. - Oxis International, Inc., through a wholly owned subsidiary, Oxis Biotech, Inc., develops innovative drugs focused on the treatment of cancer and other unmet medical needs. Oxis' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
